The laboratory, as we know it today, is transformed by how we think about medical research and the discovery of medicines, as well as by the intersection of artificial intelligence and biotechnology. As some who have been made from a doctor to a technology CEO, I have witnessed first -hand how our mentality around medicine and innovation should evolve to maintain the rhythm of accelerating changes in technology. On my trip, one of the most important lessons I have learned is: You can be too intelligent for your own good.
It may sound contradictory, but when building a company or investing in new technologies, the smartest people often fall into the trap of overlying things. A brilliant idea is not always enough. He needs adequate people who may think creatively, assume risks and make it happen in the real world.
For me, the doctor’s change of the doctor to the CEO was about understanding that it is not just about medical knowledge; It is about building the appropriate ecosystem to nurture that knowledge and turn it into a real and transformative change. I think that a crucial part of that ecosystem for my company, Owkin, is a new form of intelligence: a biological artificial intelligence (base) to complement the ingenious human minds that work us. The next -generation AI tools, such as K Navigator, the Owkin agent co -pilot for researchers and K Pro for Pharma, which is in process, will allow us to understand the complete complexity of biology that has so far been human understanding.
This forms the spine of Owkin’s mission: we are creating the next -generation pharmacy focused on discovering cures and significantly improving the value of the pipe through the development of a new intelligence system capable of decoding biological truths at scale.
Ai can fill the innovation vacuum left by Pharma
As the pharmaceutical industry focuses more and more on a handful of great success, it is leaving many medical areas that are crucial for the future of medical care. Too many diseases remain without problems since traditional pharmaceuticals fight to navigate the complexity of biology to increase attention with new molecules and efficient diagnoses.
From strange diseases to precision oncology, there is an innovation gap that is perfectly positioned to fill. IA can identify opportunities previously overlooked and optimize the development of treatments that are highly personalized and directed.
Unlike traditional pharmaceutical companies that depend largely on large -scale and high -risk projects, AI companies can operate in a more agile and data -based way. We can make narrower and more informed bets, automatic delivery learning and fixed data sets to discover ideas that were once out of reach. This change allows a faster and more efficient drug discovery, with the additional benefit of offering solutions for diseases that may not have attracted the attention of Big Pharma.
Cell lines alone are not going to work
Most traditional biological research has been based on cell lines: cells eliminated from the human body and cultivated in Petri plates.
But as we look to the future, there is a growing understanding that cell lines and other traditional research methods are becoming outdated. While once it is a basic element in biomedical research, they do not precisely replicate the complexity of human biology, and cannot capture the diversity and variability that exists in real patients.
The models driven by AI are able to go beyond the limitations of the cell lines by integrating the data of both the research carried out in cells and tissues eliminated from the body (In vitro) and of the investigation carried out in living animals (In vivo). This validation approach, which incorporates multiple types and data sources, allows us to create more reliable and predictive models of human diseases.
Science advances, and so is regulation. The recent announcement of the FDA of the plans to eliminate the tests in animals in favor of the “most effective and relevant human methods” means that we are entering an era in which the therapies can be tested in human tissue models from the beginning. In collaboration with the main academic centers, Owkin has developed a patient -derived laboratory organ (a mini version of a human organ), an advance that brings us closer to drug discovery faster, more precise and human.
The combination of clinical data, genomic ideas and not only accelerates the development of new treatments, but also increases its chances of success in clinical trials.
THE LABORATORY OF THE FUTURE
The laboratory of the future will be one in which AI is in the center, guiding the discovery, improving precision and increasing efficiency. Validation using real world data will allow us to make better decisions and achieve greater success rates. The traditional research process is being altered by these new technologies, and that is something good. The future of medicine will not only depend on human experience, but on the power of AI and data to transform the way we understand and treat diseases.
The AI will deliver transformative therapies to an exponential scale, addressing the complexities of biology that traditional pharmaceutical approaches often cannot solve. Laboratories will be automated and will serve as the last patio of recreation for scientists, promoting the future of drug discovery by taking advantage of the potential of advanced AI systems.
In these dynamic laboratories, organids and agents will join to work in synergy, allowing scientists to model and simulate human biology with greater precision. The technology driven by AI will decipher biological patterns to identify patients with the most likely to respond to specific treatments, significantly improving the possibilities of success in clinical trials and beyond. The integration of seams These avant -garde tools in the laboratory environment will transform the way we address the discovery of drugs, directing diseases with a level of precision that was previously unimaginable.
Being a pioneer in the use of data, biology and AI to decode the fundamental mechanics of the disease and advance in medical science, it will be possible to establish a basis for the future of a “positive singularity” in medicine. Through this innovative ecosystem, AI can revolutionize medicine. The time to innovate is now, and the possibilities are endless.
Thomas Clozel is co -founder and CEO of Owkin.